Recruiting PHASE3 INTERVENTIONAL 2-arm NCT04138212

Neoadjuvant Chemotherapy Versus Neoadjuvant Chemoradiotherapy for Resectable Locally Advanced Esophageal Cancer (HCHTOG1903) (HCHTOG1903)

Neoadjuvant Chemotherapy Versus Neoadjuvant Chemoradiotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma: a Randomized, Controlled Clinical Trial (HCHTOG1903)

Sponsor: Henan Cancer Hospital

Conditions Esophageal Squamous Cell Carcinoma

Interventions Paclitaxel, Cisplatin neoadjuvant chemoradiation therapy

Updated 6 times since 2019 Last updated: Aug 8, 2022 Started: Oct 22, 2019 Primary completion: Dec 21, 2023 Completion: Dec 21, 2028

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Esophageal Squamous Cell Carcinoma and is currently actively recruiting participants. Henan Cancer Hospital leads this study, which shows 6 recorded versions since 2019 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Recruiting PHASE3
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE3
Sep 2022 — Jul 2024 [monthly]

Recruiting PHASE3
Jan 2021 — Sep 2022 [monthly]

Recruiting PHASE3
Dec 2019 — Jan 2021 [monthly]

Recruiting PHASE3

▶ Show 1 earlier version

Nov 2019 — Dec 2019 [monthly]

Recruiting PHASE3

First recorded

Oct 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Henan Cancer Hospital

Data source: Henan Cancer Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Zhengzhou, China